Published in Elder Law Weekly, November 2nd, 2005
"The MTLR represents a clinically useful pharmacological target, as agonists binding to the MTLR have gastroprokinetic properties," wrote L. Xu and colleagues, University of Leuven.
"In order to compare the molecular basis for interaction of the MTLR with motilin and with the non-peptide motilin agonist, EM-A, the negatively charged E119 located in the third transmembrane (TM3) region was mutated to D (E119D) and Q (E119Q), respectively, and changes in activity of the mutant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.